Health centers must report all cases of hepatitis C to federal officials, but a study suggests that all but one case of hepatitis C went unreported in Massachusetts in a ... Read more
The novel development of safer, more effective oral medications to address hepatitis C has led to breakthrough therapies that cost patients tens of thousands of dollars for a 12-week regimen, however, investing in these therapies ... Read more
The treatment options available to address chronic hepatitis C, a serious and life-threatening infection, have substantially improved over the years, and an ever-increasing number of novel HCV regimens with shorter treatment duration ... Read more
Benitec Biopharma recently announced an agreement with Omnia Biologics, a Maryland-based biotechnology company, to manufacture materials for the TT-034 trial, the first-in-man clinical trial for hepatitis C treatment. The agreement was ... Read more
AbbVie recently presented new outcomes from the Phase 3 GIFT-I study of its all-oral, investigational, interferon (IFN)- and ribavirin (RBV)-free, 2-direct-acting antiviral treatment, ombitasvir/paritaprevir/ritonavir. The presentation took place at the Annual Meeting of the Japan ... Read more
The daclatasvir-sofosbuvir regimen for the treatment of genotype 1 hepatitis C patients was granted amended Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA). In the beginning of 2015, ... Read more
Findings from a new study recently published in the journal Cellular and Molecular Gastroenterology and Hepatology, the official journal American Gastroenterological Association, determined that a novel blood test is able ... Read more
Hepatitis C is one of the worst forms of liver diseases affecting people in the world today — around 3.2 million have HCV in the United States alone. Spread mostly from ... Read more
In a recent press release from Bristol-Myers Squibb, officials announced the success of their ongoing phase III clinical trial, ALLY-1, in meeting its predicted end-points. The trial had been conducted among ... Read more
Gilead Sciences, Inc. recently announced in a press release the promising results from several Phase 2 clinical trials assessing the use of Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) and Sovaldi® (sofosbuvir ... Read more
